Benchmark analyst Matthew Harrigan maintains Comcast (NASDAQ:CMCSA) with a Buy and lowers the price target from $60 to $46.
IDEAYA Announces Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma; Confirmed Overall Response Rate Of 45%,…
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma (MUM) patients (ClinicalTrials.gov Identifier: NCT03947385).
